SSA
AARD

Schonfeld Strategic Advisors’s Aardvark Therapeutics AARD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,131
Closed -$658K – 2786
2025
Q4 		$658K Sell
50,131
-203,621
-80% -$2.54M ﹤0.01% 1284
2025
Q3 		$3.37M Sell
253,752
-25,506
-9% -$288K 0.02% 776
2025
Q2 		$3.78M Buy
279,258
+135,307
+94% +$1.39M 0.03% 672
2025
Q1 		$1.08M Buy
+143,951
New +$1.62M 0.01% 1255

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Schonfeld Strategic Advisors's AARD Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 50,131 shares — an estimated $658K sold.

Schonfeld Strategic Advisors first reported a position in AARD in Q1 2025 and held it in 4 quarters. The position peaked at $3.78M in Q2 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 50,131 Aardvark Therapeutics shares in Q1 2026, an estimated $658K.
  • Schonfeld Strategic Advisors first reported a position in Aardvark Therapeutics in Q1 2025 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Aardvark Therapeutics position peaked at $3.78M in Q2 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.